口服氨酸抑制剂 口服氨酸抑制剂
Jan A Staessen1, Yan Li, Tom Richart
1Studies Coordinating Centre, Division of Hypertension and Cardiovascular Rehabilitation, Department of Cardiovascular Diseases, University of Leuven, Leuven, Belgium. jan.staessen@med.kuleuven.be
Lancet (London, England)
|October 24, 2006
概括
宁抑制剂阻断宁-血管酶系统,用于治疗心血管和脏疾病. 阿利斯基伦 (Aliskiren) 是一种新的口服宁抑制剂,对高血压和相关疾病有前景.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心血管医学 心血管医学
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 氨酸-血管氨系统在心血管和脏疾病中起着关键作用.
- 30多年来,抑制该系统的源头 - - 宁一直是治疗目标.
- 以前的口服宁抑制剂由于生物可用性和活性差,缺乏临床疗效.
研究的目的:
- 审查口服宁抑制剂的发展情况.
- 总结这些药物的药理动力学和药理动力学特性.
- 专注于阿利斯基伦 (aliskiren),这是第三阶段试验中的第一个非类宁抑制剂.
主要方法:
- 对口服宁抑制剂的临床前和临床数据的审查.
- 对药理动力学和药理动力学概况的分析.
- 专注于临床试验中的阿利斯基伦的进展.
主要成果:
- 阿利斯基伦是第一种口服活跃的非类宁抑制剂,已进入III期临床试验.
- 它显示出治疗高血压和相关心血管和脏疾病的潜力.
- 具有增强性质的新化合物正在临床前研究中.
结论:
- 口服氨酸抑制剂在管理氨酸-血管新生系统介导的疾病方面取得了重大进展.
- 阿利斯基伦是临床使用高血压和相关疾病的主要候选药物.
- 目前正在进行的研究旨在开发改进的口服宁抑制剂,以更好的生物可用性和疗效.
相关概念视频
Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Hormonal Regulation
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
Continuous Renal Replacement Therapy
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...

